Filing Flows › Biocryst Pharmaceuticals (BCRX) › Free cash flow
Biocryst Pharmaceuticals (BCRX) free cash flow by quarter
Biocryst Pharmaceuticals' free cash flow was $32.8M in Q3 2026 (third quarter 2026), -69% from Q2 2026. Over the last 5 quarters it ranged from $32.8M (Q3 2026) to $291M (Q4 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.8M | -69% | -19% |
| Q2 2026 | $104M | -64% | +153% |
| Q4 2025 | $291M | +623% | — |
| Q3 2025 | $40.3M | -2% | — |
| Q2 2025 | $41.1M | — | — |
Q3 2026 at a glance
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biocryst Pharmaceuticals' free cash flow?
Biocryst Pharmaceuticals' free cash flow was $32.8M in Q3 2026 (third quarter 2026), -69% from Q2 2026.
How has Biocryst Pharmaceuticals' free cash flow changed?
Over the last 5 quarters it ranged from $32.8M (Q3 2026) to $291M (Q4 2025).
Q3 2026 results → · How Biocryst Pharmaceuticals makes money →